Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal Carcinoma

Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis... Purpose: To evaluate the effect of combining circulating Epstein-Barr viral (EBV) DNA load data with TNM staging data in pretherapy prognostication of nasopharyngeal carcinoma (NPC). Patients and Methods: Three hundred seventy-six patients with all stages of NPC were studied. Pretreatment plasma/serum EBV DNA concentrations were quantified by a polymerase chain reaction assay. Determinants of overall survival were assessed by multivariate analysis. Survival probabilities of patient groups, segregated by clinical stage (I, II, III, or IV) alone and also according to EBV DNA load (low or high), were compared. Results: Pretherapy circulating EBV DNA load is an independent prognostic factor for overall survival in NPC. Patients with early-stage disease were segregated by EBV DNA levels into a poor-risk subgroup with survival similar to that of stage III disease and a good-risk subgroup with survival similar to stage I disease. Conclusion: Pretherapy circulating EBV DNA load is an independent prognostic factor to International Union Against Cancer (UICC) staging in NPC. Combined interpretation of EBV DNA data with UICC staging data leads to alteration of risk definition of patient subsets, with improved risk discrimination in early-stage disease. Validation studies are awaited. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Oncology Wolters Kluwer Health

Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal Carcinoma

Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/plasma-epstein-barr-viral-deoxyribonucleic-acid-quantitation-y599h3XApN

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
(C) 2006 American Society of Clinical Oncology
ISSN
0732-183X
eISSN
1527-7755
DOI
10.1200/JCO.2006.07.7982
Publisher site
See Article on Publisher Site

Abstract

Purpose: To evaluate the effect of combining circulating Epstein-Barr viral (EBV) DNA load data with TNM staging data in pretherapy prognostication of nasopharyngeal carcinoma (NPC). Patients and Methods: Three hundred seventy-six patients with all stages of NPC were studied. Pretreatment plasma/serum EBV DNA concentrations were quantified by a polymerase chain reaction assay. Determinants of overall survival were assessed by multivariate analysis. Survival probabilities of patient groups, segregated by clinical stage (I, II, III, or IV) alone and also according to EBV DNA load (low or high), were compared. Results: Pretherapy circulating EBV DNA load is an independent prognostic factor for overall survival in NPC. Patients with early-stage disease were segregated by EBV DNA levels into a poor-risk subgroup with survival similar to that of stage III disease and a good-risk subgroup with survival similar to stage I disease. Conclusion: Pretherapy circulating EBV DNA load is an independent prognostic factor to International Union Against Cancer (UICC) staging in NPC. Combined interpretation of EBV DNA data with UICC staging data leads to alteration of risk definition of patient subsets, with improved risk discrimination in early-stage disease. Validation studies are awaited.

Journal

Journal of Clinical Oncology – Wolters Kluwer Health

Published: Dec 1, 2006

References

  • UICC TNM Classification of Malignant Tumours (ed 5)
    Sobin LH; Wittekind CH Gestational trophoblastic tumours; in
  • Microsatellite alterations in serum DNA of head and neck cancer patients
    Nawroz H; Koch W; Anker P
  • Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma
    Mutirangura A; Pornthanakasem W; Theamboonlers A
  • Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma
    Lo YMD; Chan LYS; Lo KW
  • Real time quantitative PCR
    Heid CA; Stevens J; Livak KJ
  • Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma
    Chan AT; Lo YM; Zee B
  • Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma
    Lin JC; Wang WY; Chen KY
  • Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA
    Lo YM; Chan AT; Chan LY
  • Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type
    Leung SF; Chan AT; Zee B
  • UICC TNM Classification of Malignant Tumours (ed 5)
    Sobin LH; Wittekind CH Pharynx; in
  • AJCC Cancer Staging Manual (ed 5)
    Fleming ID; Cooper JS; Henson DE (eds)
  • World Health Organization
    Shanmugaratnam K; Sobin LH
  • Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma
    Chan AT; Leung SF; Ngan RK
  • TNM: Principles, history, and relation to other prognostic factors
    Sobin LH
  • Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099
    Al-Sarraf M; LeBlanc M; Giri PG
  • Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival
    Lin JC; Jan JS; Hsu CY
  • Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: A factorial study
    Kwong DL; Sham JS; Au GK
  • Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: Results of a meta-analysis of 1,528 patients from six randomized trials
    Huncharek M; Kupelnick B
  • The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature
    Langendijk JA; Leemans CR; Buter J
  • Treatment outcome after radiotherapy alone for patients with stage I-II nasopharyngeal carcinoma
    Chua DT; Sham JS; Kwong DL
  • Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience
    Lee N; Xia P; Quivey JM
  • Disparity of sensitivities in detection of radiation-naive and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2
    Leung SF; Lo YM; Chan AT
  • Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma
    Wong TS; Kwong DL; Sham JS
  • Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharyngeal carcinoma patient
    Chang HW; Chan A; Kwong DL